Good morning Wake-Up Watchlisters! While you're sipping coffee you'll see stock futures rose on Tuesday. Right now expectations are the latest inflation report will show the lowest figure this year, meaning a less hawkish stance on interest rates from the Federal Reserve is more possible. If you're looking to see how we're playing the Federal Reserve's latest announcement this week, we invite you to check out The War Room. We have a 77% win rate in 2022 and right now we're guaranteeing members receive 252 winning trades in their first 12 months of membership. Click here to unlock The War Room. Here's a look at the top-moving stocks this morning. Mirati Therapeutics (Nasdaq: MRTX) Mirati Therapeutics is up 14.95% premarket after winning FDA approval for Amgen-rivaling cancer drug Krazati. It's the second drug to hit the market that blocks a specific mutation in a protein called KRAS. The FDA granted Krazati accelerated approval, meaning it can now undergo further testing. The approval came after a midstage study showed 43% of patients responded to treatment. FDA Approvals can lead to big gains for biotech stocks – and there's one company in the medical sector that has also received FDA approval. Right now its device is being used at the top 100 hospitals and it's trading at just under $3. Our friend Alexander Green talks all about it here. Netcapital Inc. (Nasdaq: NCPL) Netcapital is up 47.29% premarket after announcing 71% revenue growth for the first half of fiscal 2023. The entrepreneur mentorship group posted $3.1 million in overall revenue, and also paid down $1 million in debt. CEO Cecilia Lenk cited 'strong business trends' as the primary fuel for its growth. |
No comments:
Post a Comment